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Acute myocardial uptake of digoxin was measured at a
constant paced heart rate (75 beats/min) for 30 min after an
intravenous bolus injection of 500 pg of digoxin in 14
patients with ischemic heart disease. Myocardial digoxin
content, determined by serial measurement of aortocoro-
nary sinus digoxin concentration gradients and coronary
sinus blood flow, was expressed relative to coronary sinus
blood flow at rest and correlated with simultaneous hemo-
dynamic and electrocardiographic changes.
Myocardial digoxin uptake was extensive (4.1 ± 0.7% of
total injected dose at 30 min) and prolonged, with rapid
initial uptake (75.3 ± 6.6% of maximum at 3 min),
followed by a variable phase of slower accumulation. Peak
left ventricular positive first derivative of left ventricular
pressure (dP/dt) increased progressively (p < 0.01), with a
similar time course to that of myocardial digoxin accumu-
Acute intravenous administration of digoxin in humans is
often indicated in the management of supraventricular ar-
rhythmias (such as atrial fibrillation) and sometimes in the
management of heart failure (1-5). Although the nature and
time course of acute hemodynamic and electrocardiographic
(ECG) responses to other digitalis glycosides has been
examined extensively in humans (6-11), less information is
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lation; maximal change was 18.5 ± 4.7% at 27 min. The
ratio of inotropic effect to myocardial digoxin content did
not vary significantly over the period of the experiment.
However, peak inotropic effects in individual patients were
not significantly related to peak myocardial digoxin con·
tent. The spontaneous PR interval increased transiently,
with a peak increase of 5.9 ± 1.8% (p < 0.05) 12 min after
digoxin administration.
It is concluded that after intravenous bolus administra-
tion, 1) peak effects of digoxin on atrioventricular (AV)
conduction occur early, whereas positive inotropic effects
increase progressively for ?:.27 min; and 2) digoxin accu-
mulation in the human myocardium is prolonged and is a
determinant of inotropic effects, but not of prolongation of
AV node conduction.
(J Am Coli CardioI1990;15:1238-47)
available for digoxin. However, from existing studies (12-
18), it appears that hemodynamic responses to digoxin vary
both in time course and extent. The mechanisms of this
variability are currently unknown.
In vitro (19,20) and intact animal (21,22) studies have
established a correlation between the myocardial content of
various cardiac glycosides and acute drug effect. However,
acute uptake of digoxin by the myocardium has not previ-
ously been measured in humans and the potential role of this
aspect of digoxin pharmacokinetics remains uncertain. We
(23) recently utilized the technique of coronary sinus cathe-
terization to determine the acute myocardial handling of
lidocaine and mexiletine. We now report an extension of this
technique to study the acute uptake of digoxin by the heart
in patients with ischemic heart disease and to correlate
myocardial digoxin content with some of the acute hemody-
namic and ECG effects of the drug.
Methods
Study patients. Seventeen patients undergoing cardiac
catheterization for investigation of chest pain were studied.
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All patients gave written informed consent, and the protocol
was approved by the hospital ethics committee. Excluded
were patients within 3 months of acute myocardial infarction
and those with unstable angina, prolonged chest pain or
hypotension during diagnostic angiography, hemodynami-
cally significant (>50%) left main coronary artery stenosis,
significant valvular heart disease or severe impairment of left
ventricular function (ejection fraction <30%). No patient
had received digoxin during the 30 days preceding the study.
Routine antianginal medication (including beta-adrenoceptor
or calcium antagonists, or both) was continued to the time of
cardiac catheterization.
Catheter placement. Routine catheterization was per-
formed after premedication with oral diazepam and diphen-
hydramine. Sheaths were inserted into the right femoral
artery and vein, and all patients underwent right and left
heart catheterization and cardiac output measurement by the
Fick technique; selective coronary angiography and ventric-
ulography were performed utilizing the Judkins technique.
Subsequently, the 7F thermodilution Swan-Ganz catheter
previously inserted for right heart catheterization was repo-
sitioned in the pulmonary artery for cardiac output measure-
ment. An 8F coronary sinus catheter (Webster Laborato-
ries), introduced by a left antecubital venous cutdown, was
used for coronary sinus blood flow measurement, blood
sampling and pacing. Correct placement of the catheter was
confirmed by measurement of coronary sinus blood oxygen
saturation and injection of 3 to 5 ml of radiographic contrast
medium. The latter ensured the location of the catheter's
external thermistor within the coronary sinus ostium, avoid-
ing distortion of coronary sinus flow measurement by reflux
of blood from the right atrium (24). The catheter was fixed
externally, and stable position was checked fluoroscopically
during the subsequent procedure. A4F Millar micromanom-
eter-tipped catheter was inserted through the femoral artery
sheath and positioned in the left ventricle for measurement
ofleft ventricular pressure and its first derivative (dP/dt). At
least 30 min elapsed between the last injection of radio-
graphic contrast medium and baseline predigoxin hemody-
namic assessment (25).
Protocol. The hemodynamic effects and myocardial up-
take of digoxin were studied for 30 min after intravenous
bolus drug injection. After catheter placement, pacing at 75
beats/min by means of the coronary sinus catheter was
initiated. Duplicate baseline measurements were then made
of coronary sinus blood flow, electrocardiographic (ECG)
variables (spontaneous heart rate and PR interval during
temporary interruption of pacing), hemodynamic indexes
(mean arterial pressure, cardiac index, left ventricular pres-
sure and dP/dt) and oxygen saturation in the femoral artery
and coronary sinus blood. In addition, blood samples for
baseline measurement of digoxin concentration were drawn
from the femoral artery, coronary sinus, femoral vein and
peripheral vein.
Digoxin (500 p.,g) was then administered as a bolus
injection into a rapidly flowing intravenous line situated in
the left arm. Repeat measurements were made of coronary
sinus blood flow, ECG variables, hemodynamic indexes and
blood oxygen saturation (as outlined above) at intervals 00,
8, 12, 18 and 27 min after digoxin administration. Blood
samples for measurement of digoxin concentration were
drawn simultaneously from the femoral artery, coronary
sinus, femoral vein and a peripheral vein in the right arm.
Samples were withdrawn every 30 s for the first 3 min, then
at 4,5,7.5, 10, 15,20,25 and 30 min after digoxin injection.
Additional samples were withdrawn from the femoral artery
only at 15 and 45 s to minimize error due to anticipated rapid
changes in arterial drug concentrations.
After completion ofmeasurements and sampling (30 min
after the administration of digoxin), all central catheters
were removed, but peripheral venous sampling was contin-
ued for 48 h for determination of the elimination pharmaco-
kinetics of digoxin.
Physiologic measurements. Hemodynamic measurements
were made at a constant paced heart rate (75 beats/min).
Coronary sinus blood flow was measured by thermodilution,
using as the indicator 5% dextrose in water at room temper-
ature infused by means of a constant volume Harvard
infusion pump at 36 mllmin according to the method of Ganz
et al. (26). Left ventricular pressure and dP/dt were mea-
sured with the 4F Millar micromanometer-tipped catheter.
Cardiac output was measured by using the Swan-Ganz
thermodilution catheter with the injectate 5% dextrose in
water at room temperature and an Edwards model 9520
cardiac output computer. For each time interval, the mean of
three or more measurements of cardiac output, each dif-
fering by <15%, was recorded. Mean arterial pressure was
monitored continuously from the right femoral artery sheath.
Oxygen saturation of coronary sinus and femoral artery
blood was measured with a reflection oximeter (American
Optical Company model SNK 800).
Heart rate and PR interval were monitored by lead II
ECG. Measurements were made from chart recordings at
100 mm/s, with spontaneous heart rate and PR interval
determined during transient (duration 5 to 10 s) interruption
of pacing. Hemodynamic recordings were displayed on a
Hewlett Packard 1309A polygraph and a Hewlett Packard
4560 recorder at paper speeds of 10, 50 and 100 mm/s.
Physiologic calculations. Systemic and coronary vascular
resistance was calculated from measurements of mean arte-
rial pressure, cardiac output and coronary sinus flow; in each
case resistance was calculated as the quotient of mean
arterial pressure over flow. Myocardial oxygen consumption
was derived from the product of coronary sinus blood flow
and the measured oxygen content gradient between the
femoral artery and coronary sinus blood.
Digoxin assay. Digoxin concentration in blood was mea-
sured by radioimmunoassay (Serono Diagnostics). The
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effective range of the standard curve was 0.5 to 8.0 ng/ml.
Where dilution of the sample was required because of
observed or anticipated high digoxin concentrations beyond
this range, this was performed (l :2, 1:5, I:20), and an
appropriate dilution standard curve was prepared and uti-
lized. The intraassay coefficient of variation for repeated
measurements of plasma digoxin concentration at 2 ng/ml
was 7.7% (n = 12), and the interassay coefficient of variation
was 14.6% (n = 12). For whole blood, the intraassay
coefficient of variation for repeated measurements ofdigoxin
concentration at 2 ng/ml was 13% (n = 12), and the interas-
say coefficient of variation was 12.6% (n = 15).
Whole blood digoxin concentration was determined ei-
ther by direct extraction of all samples into dichloromethane
(27) or by initial determination of plasma digoxin concentra-
tion, with subsequent utilization of the ratio of mean whole
blood to plasma digoxin concentration for conversion to
whole blood concentrations. In all cases, the whole blood/
plasma digoxin concentration ratio was derived from the
mean of determinations on at least four pairs of samples.
Both methods gave similar results, and the intrapatient
coefficient of variation for repeated determinations (n = 10)
of whole blood/plasma ratio was 14.7%.
Calculation of myocardial digoxin uptake. A preliminary
comparison of simultaneous blood sampling from the central
aorta and femoral artery after intravenous digoxin bolus
administration in two patients was used to demonstrate that
femoral artery digoxin concentrations were identical to those
in the central aorta during the study period. Thereafter,
femoral artery blood was used as an equivalent and conven-
ient source for determination of digoxin concentration in
blood entering the coronary circulation.
Myocardial drug uptake for the region ofthe left ventricle
drained by the coronary sinus was calculated as in previous
studies (23). Briefly, myocardial digoxin uptake was the
product of the transcoronary digoxin concentration gradient
and simultaneous coronary sinus blood flow. Cumulative
myocardial digoxin content over the 30 min sampling period
was derived from myocardial digoxin uptake. Myocardial
digoxin content was expressed relative to baseline coronary
sinus flow in each patient to overcome differences in mea-
sured baseline coronary sinus blood flow due to variable
catheter placement and, hence, facilitate comparison among
patients of changes in myocardial digoxin content.
Pharmacokinetic calculations. Digoxin elimination phar-
macokinetics were determined by modeling the venous
digoxin concentration/time profile variables with the pro-
gram AUTOAN 2 NONLIN (28). Distribution and elimina-
tion half-lives, apparent volume of distribution and total
body clearance were routinely calculated.
Statistical analysis. Two-way analysis of variance was
used to evaluate potential drug effects on hemodynamic and
ECG variables. Where significant effects were shown, two-
tailed paired t tests using Dunnett's correction for multiple
comparisons were used to determine the significance of
changes at each time interval. Changes in digoxin effect per
unit myocardial digoxin content expressed relative to base-
line coronary sinus flow against time were analyzed using
Spearman's rank correlation test. Results were expressed as
mean values ± SEM, and the level of statistical significance
was defined as p < 0.05.
Results
Patient characteristics (Table 1). Of the 17 patients stud-
ied, 3 were subsequently excluded from analysis (2 patients
because blood samples could not be withdrawn with ade-
quate frequency from the coronary sinus, and 1 patient
because malfunction of equipment precluded measurement
of coronary sinus blood flow). Of the remaining 14 patients,
there were 13 men and I woman; most had normal left
ventricular systolic function as assessed by baseline ejection
fraction and cardiac index, and the majority had significant
coronary artery disease. Six patients were being treated with
the calcium antagonist verapamil, seven with a beta-
adrenoceptor antagonist and four with a long-acting nitro-
glycerin preparation. Four patients received intravenously
administered atropine (0.3 to 0.6 mg) during routine angiog-
raphy for treatment of bradyarrhythmias and were excluded
from PR interval analysis. No patient experienced any
symptomatic adverse effects after digoxin administration.
Myocardial digoxin uptake. Figure 1 shows the mean
digoxin concentrations in femoral artery and coronary sinus
blood (Fig. lA) and mean myocardial digoxin content ex-
pressed relative to baseline coronary sinus flow (Fig. IB) in
all 14 patients after digoxin injection. The early large differ-
ence between femoral artery and coronary sinus drug con-
centrations (Fig. lA), corresponding to a rapid phase of
myocardial drug uptake, was followed by a subsequent
decrease in gradient without equalization of concentrations
during the latter period of the experiment. Thus, acute
myocardial uptake of digoxin was biphasic (Fig. IB); 75.3 ±
6.6% of the maximal measured uptake had occurred 3 min
after the drug was injected. At 30 min after digoxin injection,
mean myocardial digoxin content was 20.6 ± 3.3 /Lg, or 4.1
± 0.7% of total injected digoxin. Maximal myocardial dig-
oxin content relative to baseline coronary sinus flow was not
significantly related to the extent of coronary artery disease,
baseline cardiac index or the nature of concomitant antiangi-
nal therapy. There was no significant difference in observed
digoxin pharmacokinetics between patients receiving or not
receiving verapamil.
Hemodynamic changes (Table 2). The time course of
effects of digoxin on the hemodynamic variables measured is
summarized in Table 2. Statistically significant increases
occurred in mean arterial pressure and left ventricular dP/dt.
The increase in mean arterial pressure was small (5.1 ± 1.3
mm Hg) and reached its peak 3 min after digoxin injection.
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Table 1. Clinical Characteristics of 14 Patients
Coronary Artery
Age (yr)/ Fick CI Disease Concurrent
Pt. No. Gender Wt(kg) EF(%) (liters/min per m2) (>70% stenosis) Treatment
I 59/M 67.5 85 2.32 LAD,RCA N,CA
2 56/M 74 41 2.11 LAD, LCx, RCA N, B
3 50/M 80 64 2.23 LAD,RCA CA,B
4 63/M 77 45 2.02 LAD,RCA B
5 53/M 70.5 74 2.23 LAD,LCx B
6 54/M 66 76 3.2 LAD, LCx, RCA B
7 511M 71 59 3.31 LAD, LCx, RCA CA
8 55/F 66 49 2.62 LAD,RCA N,B
9 64/M 86 81 2.39 CA
10 64/M 79 71 2.73 LCx, RCA CA
II 58/M 64 34 1.93 LAD CA
12 73/M 90 70 3.23 LAD, LCx, RCA N,B
13 47/M 80 83 2.92 LAD
14 48/M 100 70 3.10 LAD
Mean 56.8 76.5 64.4 2.60
± SEM 2.0 2.8 4.4 0.13
B = beta-adrenoceptor antagonist; CA = calcium antagonist; CI = cardiac index; EF = left ventricular ejection fraction; F = female; LAD = left anterior
descending coronary artery; LCx = left circumflex coronary artery; M = male; N = long-acting nitroglycerin; Pt. = patient; RCA = right coronary artery.
There was a simultaneous small nonsignificant increase in
systemic vascular resistance. Although there was consider-
able interindividual variation in the measured changes in left
ventricular dP/dt after digoxin administration, overall a
statistically significant progressive increase in left ventricu-
lar dP/dt at constant heart rate occurred during the study
(Fig. 2), with a maximal increase of 18.5 ± 4.7% occurring 27
min after digoxin injection. Furthermore, left ventricular
end-diastolic pressure did not alter significantly after digoxin
administration, and there was no significant change in car-
diac index, coronary sinus blood flow or coronary vascular
resistance. Myocardial oxygen consumption tended to in-
crease, but this change was not statistically significant.
ECG changes (Table 2). Spontaneous heart rate did not
change significantly throughout the 30 min after digoxin
administration. The PR interval at spontaneous heart rate
showed a small nonsustained prolongation after digoxin
administration (Fig. 2); the peak increase occurred 12 min
after digoxin administration. There was a similar transient
small but significant prolongation of the paced PR interval
after digoxin administration.
Correlations between myocardial drug content and hemo-
dynamic effects. The major hemodynamic effect of digoxin
in the current study was an increase in left ventricular dP/dt
at constant heart rate. To examine the hypothesis that this
change was proportional to myocardial digoxin concentra-
tion, the relation between left ventricular dP/dt and myocar-
dial digoxin content expressed relative to baseline coronary
sinus flow was determined throughout the experiment (Fig.
3). Although the results suggest some progressive increment
in inotropic effect per unit myocardial digoxin content during
the measurement period, interindividual variation was con-
siderable and the change was not statistically significant.
Furthermore, in individual patients, there was no significant
correlation between myocardial digoxin content expressed
relative to baseline coronary sinus flow and the extent of the
increase in left ventricular dP/dt at any time after drug
administration.
Peripheral digoxin uptake. The digoxin concentration in
the femoral artery and femoral vein for 30 min after acute
intravenous bolus injection of digoxin is depicted in Figure 4.
There was a persistent arteriovenous concentration gradient
for digoxin consistent with prolonged net uptake of digoxin
into the lower limbs throughout the study period.
Digoxin elimination pharmacokinetics. Digoxin elimina-
tion kinetics conformed most closely to a two compartment
model. Mean elimination half-life of digoxin was 36.3 ± 6.7
h, and apparent volume of distribution was 7.91± 0.93
liters/kg. No significant differences in digoxin elimination
pharmacokinetics were observed between patients receiving
or not receiving verapamil.
Discussion
The current study describes the use of coronary sinus
catheterization to determine, for the first time in humans, the
characteristics of acute myocardial digoxin uptake. More-
over, it was possible to compare myocardial digoxin uptake
with hemodynamic and ECG effects of digoxin.
Previous studies. Previous studies have shed some light
on the process of myocardial uptake of digoxin. In vitro,
uptake of drugs into guinea pig atria in organ baths has been
shown to be related to drug lipophilicity and intracellular
binding (29). Kuschinsky et al. (30,31) showed tissue equil-
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Figure 1. A, Time course of whole blood digoxin concentration in
femoral artery (FA) and coronary sinus (CS) over 30 min after
intravenous bolus injection of digoxin (500 fJ-g). B, Time course of
myocardial uptake of digoxin. Calculated myocardial digoxin con-
tent is expressed relative to baseline coronary sinus (CS) blood flow.
ibration of cardiac glycoside in this model to occur over 1to
3 h, to be variable in extent (greater for the nonpolar
digitoxin than digoxin and the polar compound ouabain;
tissue to medium ratios 1011, 1.5-3/1 and 0.5-0.7/1, respec-
tively) and to be accelerated by electrical stimulation, pos-
sibly by means of increased mechanical activity.
The process of myocardial uptake of digoxin has been
extensively studied in dogs (21,22,32-35), usually by tech-
niques involving serial sacrifice or myocardial biopsy. Re-
sults suggest that net digoxin uptake continues for 2: 15 min
(21) and perhaps as long as 60 min (32) after intravenous
bolus injection, with more rapid uptake in the initial phase
(21,32). Higher concentrations occur in the ventricles than
the atria (21). Digoxin uptake is increased by tachycardia
(34) and elevation of myocardial mechanical work load (35).
In humans, myocardial/serum concentration ratios of
digoxin at steady state or within 48 h of drug withdrawal
before cardiac surgery have been reported over a wide
range: from 23.9/1 to 70/1 for the right atrium (36-38) and
from 31/1 to 70.6/1 for papillary muscle (38-41). Anumber of
investigators (42-44) also previously reported attempts in
human subjects to determine the acute myocardial uptake of
digitalis glycosides utilizing coronary sinus catheterization,
although digoxin uptake has not been examined. Marks et al.
(42) found that net uptake of 3H-ouabain by the myocardium
was maximum approximately 4 min after drug injection.
Selden and Neill (43) reported similar rapid myocardial
uptake of ouabain. A third study (44) examining myocardial
uptake of beta-methyldigoxin utilized infusion rather than
bolus administration of drug, and failed to demonstrate an
uptake phase. All of these studies were further limited by
factors such as failure to serially measure coronary sinus
blood flow and measurement of plasma rather than whole
blood drug concentration, and therefore yielded no quanti-
tative information on global myocardial drug content.
Digoxin uptake by the myocardium cannot be equated
with binding to "receptors" and thus inhibition of sodium-
potassium adenosine triphosphatase (Na+-K+ ATPase);
only a small proportion of total myocardial digoxin is recep-
tor-associated (30,31,45). Hougen and Smith (46) demon-
strated a progressive increase in peak positive left ven-
tricular dPldt and decrease in myocardial rubidium uptake
from 1 to 2 h after commencement of intravenous infusion
of ouabain despite nearly constant myocardial ouabain
concentrations, suggesting an increase with time in the
ratio of specific to nonspecific ouabain receptor binding.
Given the more extensive specific binding of ouabain within
myocardium, it might be expected that a closer relation
between myocardial glycoside content and effect would
exist for ouabain than for digoxin. Nevertheless, previous
studies have shown a correlation between myocardial dig-
oxin concentration and the extent of positive inotropic
effects in isolated guinea pig atria (19) and intact dogs
(21,32).
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Table 2. Hemodynamic Effects of Digoxin in 14 Patients
Baseline 3 Min 8 Min 12 Min 18 Min 27 Min pValue
Mean arterial pressure 94.7 ± 5 99.8 ± 5.1 98.5 ± 4.6 98.2 ± 4.9 99.8 ± 5.1 99.2 ± 4.8 <0.05
(mmHg)
Cardiac index (liters/min 2.34 ± 0.1 2.35 ± 0.15 2.43 ± 0.14 2.35 ± 0.12 2.47 ± 0.11 2.37 ± 0.13 NS
per m2)
Systemic vascular resistance 1,606 ± 72 1,766 ± 158 1,664 ± 125 1,690 ± 116 1,632 ± 110 1,736 ± 138 NS
(dyne's'cm-5)
LV positive dP/dt (mm Hg/s) 1,319 ± 110 1,417 ± 117 1,441 ± 121 1,509 ± 122 1,538 ± 126 1,554 ± 119 <0.01
LVEDP (mm Hg) 15.6 ± 2.1 15.5 ± 2.3 14.5 ± 2.1 15.1 ± 2.3 13.6 ± 2.1 14.3 ± 2.2 NS
CS flow (ml/min) 176 ± 31 167 ± 19 155 ± 19 161 ± 21 178 ± 28 166 ± 20 NS
Coronary vascular resistance 0.74±0.11 0.75 ± 0.1 0.77 ± 0.11 0.74 ± 0.09 0.72 ± 0.08 0.73 ± 0.09 NS
(mm Hg'min'ml- 1)
Myocardial oxygen 14.0 ± 1.7 14.1 ± 2 13.7 ± 1.6 15.2 ± 3 15.6 ± 3.9 16.4 ± 2.2 NS
consumption (ml/min)
Spontaneous heart rate 58.6 ± 2.4 58.9 ± 3.9 59.6 ± 3.5 59.5 ± 3.7 58.2 ± 3.4 62.1 ± 3.4 NS
(beats/min)
Spontaneous PR interval (s) 0.185 ± 0.012 0.184 ± 0.011 0.189 ± 0.011 0.196 ± 0.013 0.191 ± 0.012 0.188 ± 0.012 <0.05
Paced PR interval (s) 0.170 ± 0.018 0.165 ± 0.018 0.171 ± 0.017 0.178 ± 0.019 0.180 ± 0.021 0.171 ± 0.018 <0.05
Values are mean values ± SEM. CS = coronary sinus; LV = left ventricle; LVEDP = left ventricular end-diastolic pressure.
Figure 2. Time course of myocardial digoxin uptake expressed as
myocardial digoxin content (MDC) relative to baseline coronary sinus
(CS) blood flow, percent change in mean arterial pressure (8MAP),
percent change in left ventricular peak positive dP/dt (oLVdP/dt) and
change in spontaneous PR interval expressed as percent change from
predigoxin PR interval (0 spontaneous PR interval) for 30 min after
intravenous bolus injection of digoxin. *p < 0.05; **p < 0.01.
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In early studies (47-49) of the time course of digoxin-
induced slowing of ventricular rates in patients with rapid
atrial fibrillation and heart failure, a reduction in ventricular
rate was observed within 5 to 10 min, and maximal effect was
observed 1 to 2 h after intravenous bolus injection of
digoxin. Most previous investigations of the time course of
the acute inotropic effects of cardiac glycosides utilized
ouabain rather than digoxin. Both ouabain (50) and beta-
methyldigoxin (44) produced progressive increments in left
ventricular dP/dt for 2:20 min after intravenous administra-
tion in humans, whereas peak effects of digoxin on indexes
of contractility measured by means of systolic time intervals
occurred approximately 60 min after injection (15,51). In
dogs, digoxin induced a progressive increase in left ventric-
ular dP/dt for 2:60 min after injection (21,32,33,52).
Current results: myocardial digoxin uptake. In our inves-
tigation, after the early development of a large arterial-
coronary sinus digoxin concentration gradient. a narrow
concentration gradient persisted throughout the 30 min of
the study. Thus, digoxin uptake by the myocardium was
prolonged, and apparently biphasic. This finding of pro-
longed net uptake of digoxin by the myocardium is consist-
ent with the majority of studies (21,22,32,33) previously
performed in intact animals. Furthermore, digoxin uptake
was extensive, with peak myocardial digoxin content of 4.1
± 0.7% of injected digoxin dose. The results contrast with
previous analogous investigations from our laboratory for
lidocaine and mexiletine (23), the uptake of which was
considerably less extensive and more transient. Maximal
myocardial digoxin content expressed relative to baseline
coronary sinus flow appeared to be independent of the extent
of coronary artery disease, concurrent drug therapy and
cardiac index (although most of our patients had normal
baseline left ventricular function).
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Figure 3. Time course of the relation between the increment in left
ventricular dP/dt (expressed as percent change from predigoxin left
ventricular dP/dt [% &:IP/dt x WZj) and myocardial digoxin content,
expressed as myocardial digoxin content relative to baseline coro-
nary sinus blood flow (MDC:F) (nglml per min) for 30 min after
intravenous bolus injection of digoxin.
Pharmacologic effects of digoxin. Digoxin induced signif-
icant increases in myocardial contractility as measured by
changes in left ventricular dP/dt. Prolongation of the ECG
PR interval and increased mean arterial pressure were also
observed. All of these changes are consistent, both qualita-
tively and quantitatively, with the results of previous inves-
tigations (7,50,53-55) of digitalis glycoside effects in humans.
However, given the paucity of previously available informa-
tion concerning the time course of digoxin effects in humans,
it is important to note that a statistically significant increase
in left ventricular dP/dt occurred 3 min after drug injection
and that the maximal observed effect (18.5% increase after
27 min) was comparable in extent with maximal changes
previously documented (9,50) with other cardiac glycosides
in humans.
Hemodynamic effects. Under the conditions of the
present study, in which digoxin administration induced no
major changes in variables of preload (left ventricular end-
diastolic pressure) or afterload (mean arterial pressure and
systemic vascular resistance), it is likely that changes in left
Figure 4. Time course of whole blood digoxin concentration in
femoral artery (FA) and femoral vein (FV) over 30 min after bolus
injection of digoxin (500 J.tg).
ventricular dP/dt at a constant heart rate represent a reliable
quantitative index of the effects of digoxin on contractility
(56-59). There was also a major disparity between the time
course of the small observed increase in mean arterial
pressure (maximal 3 min after digoxin administration) and
the progressive increase in left ventricular dP/dt throughout
the experiment. The choice of a study group of patients with
generally good left ventricular function may have precluded
detection of any increase in cardiac output after digoxin
administration (60).
The time course ofthe most marked effect ofdigoxin, the
increase in left ventricular dP/dt, correlated moderately well
with that of myocardial digoxin uptake, although the extent
of the increase in left ventricular dP/dt tended to be dispro-
portionately small during the first few minutes of digoxin
uptake. Possible reasons for this minor disparity in time
course (Fig. 2) cannot be determined from the results of our
study. However, as postulated by Lullmann et at. (29), one
might suggest that much of the initial digoxin uptake, while
intramyocardial, remains extracellular at that time. Further-
more, there may be a "biochemical lag phase"-the time
required for development of maximal intracellular electro-
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lyte changes after digoxin binding to sodium-potassium
adenosine triphosphatase (61). Also, the ratio of specific to
nonspecific glycoside receptor binding may increase with
time, as suggested in the experiments of Hougen and Smith
(46).
Effect on AV conduction. The PR interval prolongation
seen in our patients is consistent with the known slowing of
atrioventricular (AV) conduction produced by cardiac gly-
cosides (53-55). However, the time course of this effect, not
previously well documented for digoxin in humans, differed
from that of the inotropic response: maximal PR interval
prolongation was seen 12 min after digoxin administration,
and then the PR interval returned toward the baseline value.
Because the effects of digoxin on AV conduction reflect
predominantly parasympathetic stimulation (53-55, 62,63), a
disparity between myocardial drug content and this effect is
not surprising. Furthermore, it is possible that the kinetics of
drug delivery to the region of the AV node may differ
significantly from those of global myocardial drug uptake. A
further possibility is that the time course of PR interval
prolongation might be explained by the penetration of digox-
in into the area postrema of the medulla, a region of the
central nervous system that is devoid of a blood-brain
barrier. In this regard, it is interesting that the time of peak
digoxin concentration in the cerebrospinal fluid of anesthe-
tized dogs occurred approximately 15 min after drug injec-
tion (64), similar to the time of peak PR interval prolongation
in this study and to that of peak AH interval prolongation in
other canine preparations (52). However, this observation is
somewhat at variance with other data (47-49) that have
shown that slowing of the ventricular rate response to atrial
fibrillation increases over 1h after digoxin administration. A
possible explanation for this disparity is that the effects of
digoxin on prolongation of the PR interval cannot be equated
precisely with its effects on the AV node refractory period,
the latter effects being more relevant for control of atrial
fibrillation.
Limitations of study. Concurrent drug therapy, in partic-
ular verapamil and beta-adrenoceptor antagonists, in the
majority of patients imposes a potential source of variability
on digoxin kinetics and hemodynamic effects. In our hospi-
tal, ethical considerations militated to some extent against
drug withdrawal before study of these patients, most of
whom had significant angina pectoris. Moreover, withdrawal
of therapy, especially beta-adrenoceptor antagonists, imme-
diately before study might also have influenced the results. It
is most unlikely that the effects of verapamil on the renal
clearance of digoxin (65,66) would have affected the acute
uptake of digoxin by the myocardium. Although both verap-
amil and beta-adrenoceptor antagonists may have modified
the extent of the hemodynamic and electrophysiologic ef-
fects of digoxin, it is most unlikely that such interactions
would affect the time course of digoxin-induced responses.
The effects of digoxin on the ECG PR interval represent
an effect on AV conduction. It would be of interest to also
measure the AV node refractory period because the time
course of this change may vary from that of the change in PR
interval and may be of greater relevance to the use of digoxin
in the management of atrial tachyarrhythmias.
Although coronary sinus catheterization is a valuable
technique for measuring myocardial drug uptake in humans,
there are limitations. The data obtained reflect only global
uptake by regions of myocardium drained by the coronary
sinus (up to 85% of the left ventricle [67]). Only limited
investigation of putative regional heterogeneity of uptake is
possible with this technique, and such study would require,
in selected patients, the use of a catheter modified to allow
blood sampling and blood flow measurements in both the
great cardiac vein and coronary sinus (68). Furthermore,
logistic considerations precluded prolonged investigation
and, therefore, examination of the efflux phase of acute
myocardial digoxin disposition. Finally, the patients had
relatively normal hemodynamic status at baseline, no acute
ischemia and were studied at a heart rate of 75 beats/min. It
is possible that results would have been markedly different
for patients with severely impaired left ventricular function
(3,9,17), acute ischemia (69,70) or tachycardia (23,34).
Clinical implications. In this study, we documented the
time course of the acute hemodynamic effects of intrave-
nously administered digoxin in humans. To date, this infor-
mation has been surprisingly limited, but it has important
practical implications in the acute management of atrial
fibrillation and heart failure. Furthermore, because this
study follows closely on two recent reports (71,72) that
reemphasize the beneficial effects of digoxin administration
in patients with heart failure, an examination of the deter-
minants of hemodynamic responses to digoxin in individual
patients seems particularly timely.
Digoxin induced definite and progressively increasing
acute positive inotropic effects, as measured using invasive
methods (left ventricular dP/dt), in this group of patients
with coronary artery disease but without significant impair-
ment of left ventricular function. The extent of these inotro-
pic effects was related, in general, to total myocardial
digoxin content. However, interindividual variability in
acute inotropic responses could not be accounted for by
variability in acute myocardial uptake alone; other modulat-
ing factors could not be identified in the current study. The
short time lag between the uptake of digoxin and attainment
of proportional inotropic effects implies that the time course
of receptor binding of digoxin and onset of biomedical
actions is not prolonged. In contrast, the maximal increase in
PR interval induced by digoxin occurred within 15 min of
drug administration, implying rapid onset of inhibition of AV
node conduction, which may be important in the manage-
ment of atrial fibrillation.
Finally, it was demonstrated that under the conditions of
this study, acute digoxin administration was associated with
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minimal evidence of systemic or coronary vasoconstrictor
effects, a potentially deleterious aspect of responses previ-
ously reported (73,74) for other digitalis glycosides in hu-
mans. Overall, the results of the current study strongly
support the potential utility of intravenously administered
digoxin for the initial management of both atrial tachyar-
rhythmias and heart failure.
We express our gratitude to the technical and nursing staff of the cardiac
catheterization laboratory and medical wards at Austin Hospital for their
invaluable assistance, and to A. Quinn and L. Newnham for secretarial
assistance.
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